KESTRA MED TECHNOLOGIES LTD SEC Filings

Amended Form 4 for Alfred J. Ford Jr. at Kestra Medical Technologies (KMTS). The filing retroactively reports the purchase of 20,000 common shares on 03/07/2025 at a price of $17.00 per share, acquired under the issuer's initial public offering reserved share program. Following this transaction, the reporting person beneficially owns 49,412 common shares in a direct capacity. The amendment states the shares were inadvertently omitted from prior filings. The form is signed by an attorney-in-fact for the reporting person.

Traci S. Umberger, General Counsel and Chief Administrative Officer and a director, reported an amended Form 4 correcting prior filings to show purchase of 13,500 common shares of Kestra Medical Technologies, Ltd. The transaction occurred on 03/07/2025 at $17.00 per share under the issuer's initial public offering reserved share program. Following the reported purchase, Umberger beneficially owned 134,336 common shares, held directly. The amendment states the shares were inadvertently omitted from prior filings and are now disclosed.

Kestra Medical Technologies director Mary Kay Ladone acquired 10,909 restricted stock units (RSUs) on 09/04/2025, each converting into one common share and scheduled to vest on September 4, 2026, subject to continued service. The filing also reports that 12,994 restricted common shares were automatically converted in connection with the issuer's initial public offering from previously held Class A Common Units granted October 7, 2024. Those converted restricted shares vest in three tranches: 4,331 on October 7, 2025; 4,331 on October 7, 2026; and 4,332 on October 7, 2027. The form is signed by the reporting person and identifies her as a director.

Raymond W. Cohen, a director of Kestra Medical Technologies, Ltd. (KMTS), reported two equity transactions. He purchased 17,000 common shares at $17.00 on 03/07/2025 that were reserved under the issuer's IPO reserved share program and were inadvertently omitted from earlier filings. He also received 10,909 restricted stock units (RSUs) on 09/04/2025; each RSU converts into one common share and the RSUs vest on 09/04/2026 subject to continued service. The report shows 29,994 shares beneficially owned after the March purchase and 40,903 shares beneficially owned following the RSU grant.

Conor Hanley, a director of Kestra Medical Technologies, Ltd. (KMTS), reported acquisition of 13,120 restricted stock units (RSUs) on 09/04/2025. The filing states each RSU converts to one common share. Following the reported grant, Hanley beneficially owns 13,120 shares attributable to these RSUs. The award vests in two tranches: 2,212 RSUs vest on 06/04/2026 and 10,908 RSUs vest on 09/04/2026, each contingent on continued service through the vesting date. The Form 4 was signed by an attorney-in-fact on 09/08/2025.

Jeffrey Lawrence Schwartz, a partner at Bain Capital Investors and a director/10% owner of Kestra Medical Technologies, acquired 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts to one common share and the RSUs vest on 09/04/2026 subject to continued service. After the reported acquisition Mr. Schwartz beneficially owns 10,909 shares directly and 27,019,225 shares indirectly, the latter held by Bain Charger Holdings, L.P. and West Affum Holdings, L.P., with Bain Capital entities holding controlling interests. Mr. Schwartz disclaims beneficial ownership except to the extent of his pecuniary interest.

Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts into one common share and the award will vest on 09/04/2026 provided Ms. Kwo remains in service through that date. The Form 4 was filed as an individual filing and signed by an attorney-in-fact, Traci S. Umberger, on 09/08/2025. This disclosure reports a non-derivative equity grant to an insider rather than a market sale or open-market purchase; no option exercise, sale price, or cash consideration is reported.

Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), reported ownership of 10,909 restricted stock units (RSUs). The RSUs each convert into one common share and are scheduled to vest on 09/04/2026, subject to her continued service. The Form 3 was filed following an event on 09/03/2025 and is the initial statement disclosing her direct beneficial ownership of these non-derivative securities.